9.180NOK+7.62%Mkt Cap: 235.51M $P/E: —Today
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three cli…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
| Headline | Source | Time |
|---|---|---|
Older | ||
IInvestornytt | ||
Circio Holding ASA (FRA:TA50) (Q2 2025) Earnings Call Highlights: Strategic Advances and ... Circio Holding ASA (FRA:TA50) showcases robust financial management and promising R&D developments in its half-year earnings call. | ||